Compare Amazon.com Inc (AMZN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amazon.com Inc vs Recursion Pharmaceuticals Inc — how do they compare? Amazon.com Inc trades at $245.2 (market cap $2.64T), while Recursion Pharmaceuticals Inc trades at $3.51 (market cap $1.89B). The key difference: Amazon.com Inc is far larger — about 1396.8× Recursion Pharmaceuticals Inc's market cap, and Amazon.com Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMZN | RXRX | |
|---|---|---|
Market Cap | $2.64T | $1.89B |
Volume | 3,931,282 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $274.95 | $6.79 |
52-Week Low | $198.79 | $2.84 |
Enterprise Value | $2.71T | $1.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amazon (AMZN) trades at $245.34, down 0.69% on the day, with strong technical momentum showing a bullish moving average signal. The company demonstrates robust fundamentals with revenue growth from $638B in 2024 to $716.9B in 2025 and net income surging to $77.67B. Recent CEO communications highlight Amazon's AI chip business reaching $20+ billion run-rate and strong visibility into future cash flows from massive capital investments.
Amazon presents a compelling investment case with 88% analyst buy ratings and a $320.75 consensus price target representing 31% upside. Key opportunities include AWS growth and AI leadership, while risks involve intense retail competition and the sustainability of massive capital expenditures. The stock's current valuation at 29.35 P/E appears reasonable given growth trajectory and profitability improvements.
RXRX trades at $3.56, down 5.32% today, with a bullish technical signal from moving averages but concerning fundamentals. The company shows deep losses with a -851.51% net income margin and negative cash flow from operations, though it has beaten earnings estimates for three consecutive quarters. Analyst consensus is mixed with a $7.83 price target representing significant upside potential from current levels.
While technical indicators suggest near-term strength and analyst targets imply 120% upside, RXRX faces substantial execution risks as a pre-revenue biotech. The company's AI-driven drug discovery platform shows promise but requires successful clinical outcomes to justify its valuation. High cash burn and negative profitability metrics present significant challenges for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amazon.com Inc
Amazon.com, Inc. is an online retailer that offers a wide range of products. The Company products include books, music, computers, electronics and numerous other products. Amazon offers personalized shopping services, Web-based credit card payment, and direct shipping to customers. Amazon also operates a cloud platform offering services globally.
Read more on AMZN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
